# Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers

> **NCT01901198** · PHASE1 · COMPLETED · sponsor: **Beijing Bio-Fortune Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
- **BIOLOGICAL:** Peginterferon 180 mcg single dose S.C.

## Key facts

- **NCT ID:** NCT01901198
- **Lead sponsor:** Beijing Bio-Fortune Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2013-09
- **Final completion:** 2013-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01901198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01901198, "Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01901198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*